title: Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
authors.affiliation: ScHARR Technology Assessment Group, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, S1 4DA Sheffield, UK. n.j.bansback@sheffield.ac.uk
authors.forename: Nick
authors.initials: N
authors.lastname: Bansback
authors.forename: Sue
authors.initials: S
authors.lastname: Ward
authors.forename: Jon
authors.initials: J
authors.lastname: Karnon
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000191:economics*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D006113:United Kingdom; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine